You may have read that a drug from an OHSU startup received FDA approval last month. In 2003, OHSU’s office of Technology Transfer & Business Development (TTBD) created a start-up company called Orexigen Therapeutics, Inc., with Michael Cowley, then a neuroscience researcher at the Oregon National Primate Research Center. Cowley’s work looks at the appetite-regulating pathways in the brain and how these pathways are affected by obesity. Orexigen Therapeutics became public in 2007, and now the drug based on this work, Contrave, is set to go live. Orexigen’s story was featured on the cover of the October 3rd edition of the Portland Business Journal, and you can read it HERE. (Update: we should let you know that the Business Journal article requires a subscription to read the entire article, though the link will give you a preview).